Form 4: Director Sells BioCryst Pharmaceuticals Stock

Director Amy E. McKee reported a sale of BioCryst Pharmaceuticals Inc. common stock valued at approximately $100,000.

Summary

• Amy E. McKee, a Director at BioCryst Pharmaceuticals Inc. (BCRX), reported a transaction on May 18, 2026.
• McKee sold 11,180 shares of common stock at a weighted average price of $8.97 per share.
• The total value of the transaction was approximately $100,290.60, with individual sales ranging from $8.96 to $8.985.
• Following this transaction, McKee beneficially owns 31,252 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the director's sale of stock, which can sometimes be interpreted as a bearish signal, though the reasons for the sale are not disclosed.

Negatives

• Director sale of a significant number of shares could be perceived negatively by the market.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling, particularly by directors, can sometimes signal a lack of confidence in near-term stock performance, although it can also be for personal financial planning reasons.

Stakeholder Impact

• Shareholders may view the director's sale as a potential negative signal, possibly impacting short-term stock sentiment.

Key Dates

Recommendation

The filing reports an insider sale, which warrants attention but does not provide sufficient information on the company's overall performance or future prospects to warrant a strong buy or sell recommendation. A 'hold' position allows investors to monitor further developments.

Keywords

BioCryst Pharmaceuticals, BCRX, Form 4, Insider Trading, Stock Sale, Director Transaction, Securities Exchange Act